Send me a link:

*Text messaging rates may apply.

 Dow Down0.31% Nasdaq Up0.25%

MediciNova Inc. (MNOV)

2.00 Up 0.04(2.04%) 12:16PM EDT - Nasdaq Real Time Price
ProfileGet Profile for:
MediciNova Inc.
4275 Executive Square
Suite 650
San Diego, CA 92037
United States - Map
Phone: 858-373-1500

Index Membership:N/A
Full Time Employees:11

Business Summary 

MediciNova, Inc., a development stage biopharmaceutical company, focuses on acquiring and developing small molecule therapeutics for the treatment of serious diseases for the United States market. The company’s principal product candidates include MN-166, an ibudilast-based drug candidate, which is in Phase I and Phase II clinical trials for the treatment of drug dependence and pain; and MN-221, a ß2 -adrenergic receptor agonist that has completed Phase II clinical trials for the treatment of acute exacerbations of asthma. It also has other product candidates in the clinical development for the treatment of acute exacerbations of asthma, multiple sclerosis and other central nervous system disorders, bronchial asthma, interstitial cystitis, solid tumor cancers, generalized anxiety disorders/insomnia, preterm labor, urinary incontinence, and thrombotic disorders. MediciNova, Inc. was founded in 2000 and is headquartered in La Jolla, California.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on MediciNova Inc.

Key Executives 
Dr. Yuichi Iwaki M.D., Ph.D., 64
Co-Founder, Chief Exec. Officer, Pres and Exec. Director
Mr. Masatsune Okajima , 46
Head of Japanese Office and VP
Dr. Kazuko Matsuda M.D., Ph.D., MPH, 48
Chief Medical Officer
Ms. Esther van den Boom ,
Chief Financial Officer
Dr. Joji Suzuki M.D., Ph.D., 52
Sr. VP of Fin. & Admin.
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders